ELF Raises Fiscal 2027 Outlook as Rhode and Global Growth Accelerate
ELF raises its fiscal 2027 outlook as Rhode outperforms expectations, international sales surge and global expansion adds growth runway.
Zacks
Is ELF Stock a Buy as Growth Accelerates but Valuation Stays Rich?
ELF's faster portfolio growth, Rhode momentum and raised fiscal 2027 outlook strengthen its case, but premium valuation and core-brand softness raise execution risks.
Zacks
EL Stock to Post Q4 Earnings: Here's What Investors Should Know
EL's fiscal fourth-quarter results are likely to benefit from fragrance momentum, key international markets and improving retail trends despite cost pressures.
Zacks
ELF Jumps 18.8% in a Week Amid Rhode Growth and Stronger Guidance
ELF's 18.8% weekly surge is backed by Rhode growth, stronger guidance and global expansion, though core softness and a premium valuation raise execution stakes.
Zacks
3 Reasons Why Growth Investors Shouldn't Overlook Ulta (ULTA)
Ulta (ULTA) possesses solid growth attributes, which could help it handily outperform the market.
Zacks
Will Ulta (ULTA) Beat Estimates Again in Its Next Earnings Report?
Ulta (ULTA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks
Will Ulta Beauty's Omnichannel Edge Help Sustain Business Growth?
ULTA is strengthening its omnichannel strategy through digital growth, loyalty, AI and social commerce to drive customer engagement.
Zacks
Is Arhaus Benefiting From Resilient High-End Consumer Demand?
ARHS posts record second-quarter revenues as resilient high-end consumers drove 12.5% comparable written sales growth and larger home projects.
Zacks
Nu Skin Enterprises Q2 Earnings Meet Estimates, Revenues Down Y/Y
NUS' second-quarter revenues fall 17.1% and EPS drops 53.5%, while it cuts the 2026 revenue and adjusted EPS outlooks.
Zacks
Is It Worth Investing in Ulta (ULTA) Based on Wall Street's Bullish Views?
Based on the average brokerage recommendation (ABR), Ulta (ULTA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Zacks